Hallux

Hallux Inc. is developing a physician-administered topical gel, HSG, for onychomycosis, utilizing a unique subungual delivery method to bypass the nail plate and deliver terbinafine directly to the infected nail bed. The company is nearing completion of a Phase 2a study and positions its product as a potential paradigm shift, combining the efficacy of oral antifungals with the safety profile of topicals. With a seasoned leadership team and a focus on a large, underserved market, Hallux seeks to address significant limitations of current treatments, including poor efficacy, long treatment durations, and systemic side effects.

Proprietary subungual drug delivery platform designed to administer therapeutics directly into the space under the nail (nail bed) via an atraumatic pathway, bypassing the nail plate barrier.

HSG competes against oral terbinafine (generic, effective but with systemic safety concerns) and FDA-approved topical antifungals (safe but with low efficacy and poor adherence). Its primary differentiation is its targeted delivery method aiming for superior efficacy without systemic exposure. It must also compete against laser devices and over-the-counter products in a crowded, cost-conscious market.